Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Relapsed/Refractory Multiple Myeloma

Relapsed/Refractory Multiple Myeloma Clinical Trial

Official title:

A Prospective, Open-label, Single-arm Clinical Study of Mitoxantrone Hydrochloride Liposome Injection Combined With Daratumumab and Dexamethasone in the Treatment of Relapsed/Refractory Multiple Myeloma

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05857982
• Other study ID #: JD-LK2023022-IR01
• Status: Recruiting
• Phase: Phase 1/Phase 2
• Start date: May 20, 2023
• Est. completion date: December 31, 2025

Study information

• Verified date: May 2023
• Source: Second Affiliated Hospital of Soochow University
• Contact: Bingzong LI
• Phone: 13776054037
• Email: lbzwz0907[@]hotmail.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A prospective, open-label, single-arm clinical study of mitoxantrone hydrochloride liposome injection combined with daratumumab and dexamethasone in the treatment of relapsed/refractory multiple myeloma

Description:

This study is a prospective, open-label, single-arm study. It is expected to include 20 patients with relapsed/refractory multiple myeloma who will receive combined treatment. The recommended dose of mitoxantrone hydrochloride liposome injection is 20mg/m2 (the dose can be adjusted according to the patient's tolerance, but the minimum dose is not less than 12mg/m2). Each cycle is 4 weeks long and the maximum number of cycles is 6. Dexamethasone 20 mg/d, on the same day of daratumumab injection; Mitoxantrone hydrochloride liposome injection: 20 mg/m2, d1; Daratumumab: 16 mg/Kg, once a week for the first 8 weeks; then changed to once every two weeks; The study includes a screening period (within 28 days), a treatment period (up to 6 cycles), and a follow-up period (safety follow-up, survival follow-up, planned for 2 years). The subjects signed an informed consent form and underwent baseline examination during the screening period. Eligible patients were enrolled in the treatment period. All subjects underwent relevant examinations as stipulated in the protocol during the treatment process to observe efficacy and safety. After the treatment period ends, they will enter the follow-up period.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 20
• Est. completion date: December 31, 2025
• Est. primary completion date: January 31, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• 1. Age :18-75 years, male or female; 2. Meet the definition of relapsed/refractory

multiple myeloma; 3. At least one of the following can be evaluated:

1. Blood M protein level =10g/L;

2. 24-hour urine M protein level =200mg;

3. The difference between involved and uninvolved serum free light chain (dFLC) =100mg/L;

4. Extramedullary lesions with a diameterday=2cm; 4. ECOG score 0-2 points; 5.

Laboratory tests meet the following criteria:

1. Absolute neutrophil count (ANC) =1.0x109/L;

2. Platelets (PLT) =50x109/L;

3. Total bilirubin (TBIL) =1.5 times the upper limit of normal (ULN);

4. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =2.5 times ULN;

5. Creatinine clearance rate (Ccr) =30ml/min.

Exclusion Criteria:

• 1.Expected survival time <3 months. 2.History of allergy to mitoxantrone or liposomal drugs; previous treatment with mitoxantrone or other anthracycline therapy, total cumulative dose of mitoxantrone >360 mg/m2 (other anthracycline drugs are equivalent to 1mg mitoxantrone, 2mg doxorubicin or 0.5mg epirubicin). 3.Impaired cardiac function or significant heart disease, including but not limited to: a) Myocardial infarction or viral myocarditis within 6 months before screening. b) Existing heart disease requiring treatment at the time of screening, such as unstable angina pectoris, chronic congestive heart failure (NYHA=2), arrhythmia, valve disease, etc., or persistent myocardial disease. c) QTc interval>480ms at screening or long QTc syndrome. d) Ejection fraction less than 50% at screening or lower than the lower limit of the study center's examination value range. 4.HBsAg or HBcAb positive and HBV-DNA titer higher than the lower limit of the study center's detection value, or HCV antibody positive and HCV-RNA titer higher than the lower limit of the study center's detection value, or HIV antibody positive. 5.Bacterial infection, fungal infection or viral infection requiring systemic treatment within 1 week before administration of the study drug. 6.Pregnant or lactating women. 7.Other situations judged by investigator as inappropriate for participation in this study.

Related Conditions & MeSH terms

• Multiple Myeloma
• Neoplasms, Plasma Cell
• Relapsed/Refractory Multiple Myeloma

Intervention

Drug:
• Mitoxantrone hydrochloride liposome/Dexamethasone/daratumumab
Dexamethasone 20 mg/d, on the same day of daratumumab injection; Mitoxantrone hydrochloride liposome injection: 20 mg/m2, d1; Daratumumab: 16 mg/Kg, once a week for the first 8 weeks; then changed to once every two weeks; Each cycle is 4 weeks long and the maximum number of cycles is 6.

Locations

Country	Name	City	State
China	Second Affiliated Hospital of Soochow University	Suzhou	Jiangsu

Sponsors (2)

Lead Sponsor	Collaborator
Second Affiliated Hospital of Soochow University	The Affiliated Hospital of Xuzhou Medical University

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	ORR	Objective response rate (ORR): Objective response includes partial response (PR), very good partial response (VGPR), complete response (CR), and strictly defined complete response (sCR).	6 months
Secondary	Adverse Eventsl	hematological and non-hematologica Adverse Eventsl (NCI CTCAE v5.0);	6 months
Secondary	DoR	Duration of response (DoR)	1 year
Secondary	1-year PFS rate	1-year progression-free survival rate (PFS)	1 year
Secondary	1-year PFS OS	1-year overall survival rate (OS)	1 year
Secondary	1-year extramedullary relapse rate.	1-year extramedullary relapse rate.	1 year